287 related articles for article (PubMed ID: 29098396)
1. Survival benefit of tamoxifen and aromatase inhibitor in male and female breast cancer.
Eggemann H; Altmann U; Costa SD; Ignatov A
J Cancer Res Clin Oncol; 2018 Feb; 144(2):337-341. PubMed ID: 29098396
[TBL] [Abstract][Full Text] [Related]
2. Optimal adjuvant endocrine treatment of ER+/HER2+ breast cancer patients by age at diagnosis: A population-based cohort study.
Dackus GMHE; Jóźwiak K; Sonke GS; van der Wall E; van Diest PJ; Hauptmann M; Siesling S; Linn SC
Eur J Cancer; 2018 Feb; 90():92-101. PubMed ID: 29274928
[TBL] [Abstract][Full Text] [Related]
3. Endocrine therapy or chemotherapy as first-line therapy in hormone receptor-positive HER2-negative metastatic breast cancer patients.
Jacquet E; Lardy-Cléaud A; Pistilli B; Franck S; Cottu P; Delaloge S; Debled M; Vanlemmens L; Leheurteur M; Guizard AV; Laborde L; Uwer L; Jacot W; Berchery D; Desmoulins I; Ferrero JM; Perrocheau G; Courtinard C; Brain E; Chabaud S; Robain M; Bachelot T
Eur J Cancer; 2018 May; 95():93-101. PubMed ID: 29655061
[TBL] [Abstract][Full Text] [Related]
4. Adjuvant therapy with tamoxifen compared to aromatase inhibitors for 257 male breast cancer patients.
Eggemann H; Ignatov A; Smith BJ; Altmann U; von Minckwitz G; Röhl FW; Jahn M; Costa SD
Breast Cancer Res Treat; 2013 Jan; 137(2):465-70. PubMed ID: 23224235
[TBL] [Abstract][Full Text] [Related]
5. Treatment adoption and relative effectiveness of aromatase inhibitors compared to tamoxifen in early breast cancer: A multi-institutional observational study.
Ferreira AR; Palha A; Correia L; Filipe P; Rodrigues V; Miranda A; André R; Fernandes J; Gouveia J; Passos-Coelho JL; Moreira A; Brito M; Ribeiro J; Metzger-Filho O; Lin NU; Costa L; Vaz-Luis I
Breast; 2018 Feb; 37():107-113. PubMed ID: 29131988
[TBL] [Abstract][Full Text] [Related]
6. Hormone Receptor-Positive Breast Cancer Has a Worse Prognosis in Male Than in Female Patients.
Li X; Yang J; Krishnamurti U; Huo L; Ward KC; O'Regan R; Peng L
Clin Breast Cancer; 2017 Aug; 17(5):356-366. PubMed ID: 28576631
[TBL] [Abstract][Full Text] [Related]
7. Overall Survival of Men and Women With Breast Cancer According to Tumor Subtype: A Population-based Study.
Leone J; Zwenger AO; Leone BA; Vallejo CT; Leone JP
Am J Clin Oncol; 2019 Feb; 42(2):215-220. PubMed ID: 30499840
[TBL] [Abstract][Full Text] [Related]
8. Androgen receptor expression in male breast cancer predicts inferior outcome and poor response to tamoxifen treatment.
Wenhui Z; Shuo L; Dabei T; Ying P; Zhipeng W; Lei Z; Xiaohui H; Jingshu G; Hongtao S; Qingyuan Z
Eur J Endocrinol; 2014 Oct; 171(4):527-33. PubMed ID: 25069458
[TBL] [Abstract][Full Text] [Related]
9. A Prognostic Analysis of Male Breast Cancer (MBC) Compared with Post-Menopausal Female Breast Cancer (FBC).
Yu XF; Yang HJ; Yu Y; Zou DH; Miao LL
PLoS One; 2015; 10(8):e0136670. PubMed ID: 26313461
[TBL] [Abstract][Full Text] [Related]
10. Male breast cancer in the veterans affairs population: a comparative analysis.
Nahleh ZA; Srikantiah R; Safa M; Jazieh AR; Muhleman A; Komrokji R
Cancer; 2007 Apr; 109(8):1471-7. PubMed ID: 17342768
[TBL] [Abstract][Full Text] [Related]
11. Men and women show similar survival outcome in stage IV breast cancer.
Wu SG; Zhang WW; Liao XL; Sun JY; Li FY; Su JJ; He ZY
Breast; 2017 Aug; 34():115-121. PubMed ID: 28577471
[TBL] [Abstract][Full Text] [Related]
12. Survival benefit of tamoxifen in male breast cancer: prospective cohort analysis.
Eggemann H; Brucker C; Schrauder M; Thill M; Flock F; Reinisch M; Costa SD; Ignatov A
Br J Cancer; 2020 Jul; 123(1):33-37. PubMed ID: 32367072
[TBL] [Abstract][Full Text] [Related]
13. Reducing the risk for breast cancer recurrence after completion of tamoxifen treatment in postmenopausal women.
Jahanzeb M
Clin Ther; 2007 Aug; 29(8):1535-47. PubMed ID: 17919537
[TBL] [Abstract][Full Text] [Related]
14. Age-related differences in persistence in women with breast cancer treated with tamoxifen or aromatase inhibitors in Germany.
Jacob L; Hadji P; Kostev K
J Geriatr Oncol; 2016 May; 7(3):169-75. PubMed ID: 27091510
[TBL] [Abstract][Full Text] [Related]
15. The impact of tumor progesterone receptor status on optimal adjuvant endocrine therapy for postmenopausal patients with early-stage breast cancer: a decision analysis.
Punglia RS; Kuntz KM; Winer EP; Weeks JC; Burstein HJ
Cancer; 2006 Jun; 106(12):2576-82. PubMed ID: 16703595
[TBL] [Abstract][Full Text] [Related]
16. Male breast cancer is not congruent with the female disease.
Fentiman IS
Crit Rev Oncol Hematol; 2016 May; 101():119-24. PubMed ID: 26989051
[TBL] [Abstract][Full Text] [Related]
17. Changing the gold standard in adjuvant therapy for breast cancer:from tamoxifen to aromatase inhibition.
Gltick S
Biomed Pharmacother; 2005 Oct; 59 Suppl 2():S321-2. PubMed ID: 16521302
[TBL] [Abstract][Full Text] [Related]
18. Patterns and reasons for switching classes of hormonal therapy among women with early-stage breast cancer.
Kwan ML; Roh JM; Laurent CA; Lee J; Tang L; Hershman D; Kushi LH; Yao S
Cancer Causes Control; 2017 Jun; 28(6):557-562. PubMed ID: 28349440
[TBL] [Abstract][Full Text] [Related]
19. Contemporary systemic therapy for male breast cancer.
Bradley KL; Tyldesley S; Speers CH; Woods R; Villa D
Clin Breast Cancer; 2014 Feb; 14(1):31-9. PubMed ID: 24220158
[TBL] [Abstract][Full Text] [Related]
20. Dachshund 1 is Differentially Expressed Between Male and Female Breast Cancer: A Matched Case-Control Study of Clinical Characteristics and Prognosis.
Cui Q; Kong D; Li Z; Ahiable P; Wang K; Wu K; Wu G
Clin Breast Cancer; 2018 Oct; 18(5):e875-e882. PubMed ID: 29478945
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
